[go: up one dir, main page]

WO2007135118A1 - Formules solubles stables contenant de l'insuline - Google Patents

Formules solubles stables contenant de l'insuline Download PDF

Info

Publication number
WO2007135118A1
WO2007135118A1 PCT/EP2007/054863 EP2007054863W WO2007135118A1 WO 2007135118 A1 WO2007135118 A1 WO 2007135118A1 EP 2007054863 W EP2007054863 W EP 2007054863W WO 2007135118 A1 WO2007135118 A1 WO 2007135118A1
Authority
WO
WIPO (PCT)
Prior art keywords
insulin
formulation
another embodiment
formulations
protamine
Prior art date
Application number
PCT/EP2007/054863
Other languages
English (en)
Inventor
Helle Birk Olsen
Niels Christian Kaarsholm
Palle Jakobsen
Per Balschmidt
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Publication of WO2007135118A1 publication Critical patent/WO2007135118A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Definitions

  • the present invention relates to pharmaceutical formulations comprising acid stabilized insulin and a salt of protamine or other positively charged peptides, to methods of pre- paring such formulations, and to uses of such formulations in the treatment of diseases and conditions for which use of the insulin peptide(s) contained in such formulations is indicated.
  • Diabetes mellitus is a metabolic disorder in which the ability to utilize glucose is more or less completely lost. About 2% of all people suffer from diabetes. Since the discovery of insulin in the 1920's, continuous strides have been made to improve the treatment of diabetes mellitus. To help avoid extreme glucose levels, diabetic patients often practice insulin replacement therapy, whereby insulin is administered by injection.
  • insulin compositions In the treatment of diabetes mellitus, many varieties of insulin compositions have been suggested and used, including regular insulin, Semilente ® insulin, isophane insulin, insulin zinc suspensions, protamine zinc insulin, and Ultralente ® insulin. As diabetic patients typically are treated with insulin for several decades, there is a major need for safe and life quality improving insulin compositions. Some of the commercially available insulin compositions are characterized by a fast onset of action, while other compositions have a relatively slow onset but show a more or less prolonged action. Fast acting insulin compositions are usually solutions of insulin, while retarded acting insulin compositions can be suspensions containing insulin in crystalline and/or amorphous form precipitated by addition of zinc salts alone or by addition of protamine or by a combination of both.
  • compositions having both a fast onset of action and a more prolonged action may be an insulin solution wherein protamine insulin crystals are suspended.
  • Some patients prepare the final composition them- selves by mixing an insulin solution with a suspension composition in the desired ratio.
  • Human insulin consists of two polypeptide chains, the so-called A and B chains, which contain 21 and 30 amino acid residues, respectively.
  • the A and B chains are interconnected by two cystine disulphide bridges and a third disulfide bridge is intra A chain.
  • Insulin from most other species has a similar construction, but may not contain the same amino acid residues at corresponding positions.
  • insulin compounds analogous to human insulin.
  • these insulin analogs one or more of the amino acid residues have been substituted with other amino acid residues which can be coded for by the nucleotide sequences. Since human insulin, as explained above, contains 51 amino acid residues, it is obvious that a large number of insulin analogs is possible, and a great variety of analogs with interesting properties have been prepared.
  • human insulin solutions with a concentration of interest for injectable compositions the insulin molecule is present in associated form as a hexamer (Brange et al. Diabetes Care 13, (1990), 923 - 954).
  • Scott and Fisher (1936) disclose suspensions of insulin containing 1 mM protamine sulphate and 0.15 mM insulin at pH 7.2.
  • compositions which are based on analogues of human insulin have e.g. been presented by Heinemann et al., Lutterman et al. and Wiefels et al. at the "Frontiers in Insulin Pharmacology" International Symposium in Hamburg, 1992.
  • US 5474 978 discloses a rapidly acting parenteral formulation comprising a human insulin analogue hexamer complex consisting of six monomeric insulin analogues, zinc ions and at least three molecules of a phenolic derivative.
  • insulin compositions are administered by subcutaneous injection. What is important for the patient is the profile of action of the insulin composition, i.e. the action of insulin on the glucose metabolism as a function of the time from the injection, including the time for the onset of insulin action, the maximum value and the total duration of action.
  • a variety of insulin compositions with different profiles of action are required by patients. An individual patient may thus on the same day use insulin compositions with very different profiles of action.
  • the profile of action required for any given patient at any given time depends upon several factors, e.g. the time of the day and the amount and composition of any meal eaten by the patient.
  • pen-like injection devices such as devices which contain Pen- fill ® cartridges
  • an insulin composition is stored until the entire cartridge is empty. This may last 1 to 2 weeks or more for devices containing a 1.5 or 3.0 ml cartridge.
  • covalent chemical changes in the insulin structure occur. This may lead to the formation of molecules which are less active and potentially immunogenic such as deamidation products and higher molecular weight transformation products (dimers, polymers, etc.).
  • a comprehensive study on the chemical stability of insulin is given by Jens Brange in "Stability of Insulin", Kluwer Academic Publishers, 1994.
  • compositions comprising insulin and insulin analogues are traditionally formulated using various additives, for example sodium phosphate (buffer), Zn 2+ (stabilizer), phenol/m- cresol (preservative and stabilizer), sodium chloride (isotonicity agent and stabilizer), and glycerol/mannitol (isotonicity agents).
  • sodium phosphate buffer
  • Zn 2+ stabilizer
  • phenol/m- cresol preservative and stabilizer
  • sodium chloride isotonicity agent and stabilizer
  • glycerol/mannitol isotonicity agents
  • insulin products are subject to the formation of insoluble aggregates (fibrils) as a result of shaking, e.g. when carried in the pocket of a patient or during transport. It is essential for the quality of an insulin product that the tendency to form such soluble and insoluble aggregates as a result of chemical or physical influences is reduced to an absolute minimum.
  • Acta Pharmaceutics Nordica 4(4), 1992, pp. 149-158 discloses insulin compositions with a sodium chloride concentration in the range of 0 to 250 mM.
  • the major part of the compo- sitions, including those which additionally comprise glycerol, contain a rather high amount of sodium chloride, i.e. 0.7%, corresponding approximately to a concentration of 120 mM.
  • US Patent No. 5,866,538 discloses insulin compositions having improved chemical stability, the compositions comprising human insulin or an analog or derivative thereof, glycerol and/or mannitol and 5-100 mM of a halogenide, e.g. sodium chloride.
  • US Patent No. 6, 174,856 discloses stabilized aqueous compositions comprising human insulin or an analog or derivative thereof, a buffer selected from glycylgly- cine, citrate or TRIS and metal ions, in particular, calcium or magnesium ions.
  • US Patent No. 6,451 ,762 (Novo Nordisk) discloses protracted acting water soluble aggregates of derivatives of human insulin.
  • US Patent No. 6,551 ,992 (EIi Lilly) discloses monomeric insulin analog formulations stabilized against aggregation in which the buffering agent is either TRIS or arginine.
  • US Patent No. 5,747,642 discloses parenteral pharmaceutical formulations which comprise a monomeric insulin analog, zinc, protamine and a phenolic derivative.
  • US Patent No. 6,465,426 discloses insoluble compositions comprising an acylated insulin or acyalted insulin analog complexed with zinc, protamine and a phenolic compound such that the resulting microcrystal is analogous to the neutral protamine Hage- dorn (NPH) insulin crystal form.
  • formulations containing certain salts of protamine or other positively charged peptides at certain concentrations allow soluble stable preparations of acid stabilized insulin, to be formulated at pHs below 5.5.
  • the present formu- lations are also physically and chemically stable at a pH below 5.5 and exhibit a prolonged profile of action thus rendering them shelf-stable and suitable for invasive (e.g. injection, subcutaneous injection, intramuscular, intraveneous or infusion ) as well as non-invasive (e.g. nasal, oral, pulmonary, transdermal or transmucosal e.g. buccal ) means of administration.
  • the present invention therefore relates to pharmaceutical formulations comprising acid stabilized insulin and a salt of protamine or other positively charged peptides where the salt is present in a concentration of at least 0.01 mM and the pH of the formulation is less than about 5.0.
  • the pharmaceutical formulations of the invention may further contain at least one of the following components: a preservative, a divalent metal ion such as zinc cobalt, magnesium or calcium or combinations of these ions, an isotonicity agent, a buffer and a surfactant.
  • the present invention further relates to methods of treatment using the pharmaceutical formulations of the invention where the compositions are administered in an amount effective to combat the disease, condition, or disorder for which administration of the insulin peptide contained in the formulation is indicated.
  • the formulations of the invention may be used in the treatment of type 1 and type 2 diabetes.
  • the present invention also relates to methods for producing the pharmaceutical formulations of the invention.
  • the method for preparing formulations of the invention com- prises: a) preparing a solution by dissolving a divalent metal ion in water or buffer; b) preparing a solution by dissolving the preservative in water or buffer; c) preparing a solution by dissolving the isotonicity agent in water or buffer ; d) preparing a solution by dissolving the surfactant in water or buffer; e) preparing a solution by dissolving the insulin, insulin analog, insulin derivative or a mixture of the foregoing in water or buffer; f) preparing a solution by dissolving a salt of protamine or other positively charged peptides in buffer or water; g) mixing solution e) and one or more of solutions a), b), c), and d); h) mixing solution g) with solution f); and i) adjusting the pH of the mixture in h)l to the desired pH of less than 5.0.
  • Figure 1 show the solubility of human insulin in the presence of 1.2mM and 2.OmM concentrations of the acetate salt of R12.
  • the preparations are 0.4mM human insulin, 25mM tricresol, 1.6% glycerol, 40 ppm tween-20 and R12 added as noted in the legends.
  • the pharmaceutical formulations of the invention comprise acid stabilized insulin and a salt of protamine or other positively charged peptides where the salt is present in a concentration of at least 0.01 mM and the pH of the formulation is less than about 5.5.
  • the pharmaceutical formulations of the invention are chemically stable and soluble at pHs less than 5.0.
  • soluble at a given pH is meant that the insulin contained in the formulation of the invention is fully dissolved at the pH of the formulation where methods for determining whether the insulin contained in the formulation of the invention is dissolved are known in the art.
  • the pharmaceutical formulation may be subjected to centrifugation for 20 minutes at 30,000 g and then the insulin concentration in the supernatant may be determined by RP-HPLC. If this concentration is equal within experimental error to the insulin concentration originally used to make the formulation, then the insulin is fully soluble in the formula- tion of the invention.
  • the solubility of the insulin peptide(s) in a formulation of the invention can simply be determined by examining by eye the container in which the formulation is contained. Insulin is soluble if the solution is clear to the eye and no particulate matter is either suspended or precipitated on the sides/bottom of the container.
  • solubility of insulin in a formulation of the invention may be affected not only by the composition of the formulation and its pH but also by the temperature and time at which the formulation is stored prior to measurement of solubility.
  • the term "acid stabilized insulin” as used herein re- fers to an analogue of human insulin that has reduced tendency to deamidate or dimerize at pH values below 7 compared to human insulin.
  • the analogue cannot have Asn or Asp as a C-terminal residue, that is an acid stabilized insulin always has a substitution of Asn in position A21 with any other amino acid with the exception of Asp.
  • the acid stabilized insulin is an analogue of human insulin wherein position B28 is Asp or GIu. In another embodiment the acid stabilized insulin is an analogue of human insulin wherein position B28 is Asp.
  • the acid stabilized insulin is an analogue of human insulin wherein position B28 is GIu. In another embodiment the acid stabilized insulin is an analogue of human insulin wherein position B29 is Pro, Asp or GIu.
  • the acid stabilized insulin is an analogue of human insulin wherein position B29 is Pro or GIu.
  • the acid stabilized insulin is an analogue of human insulin wherein position B29 is Pro.
  • the acid stabilized insulin is an analogue of human insulin wherein position B29 is GIu.
  • the acid stabilized insulin is an analogue of human insulin wherein position B28 is Asp or Lys, and position B29 is Lys or Pro. In another embodiment the acid stabilized insulin is an analogue of human insulin wherein position B9 is Asp or GIu.
  • the acid stabilized insulin is an analogue of human insulin wherein position B10 is Asp or GIu or GIn.
  • the acid stabilized insulin is an analogue of human insulin wherein position B10 is GIu.
  • the acid stabilized insulin is an analogue of human insulin wherein position B10 is GIn.
  • the acid stabilized insulin is an analogue of human insulin wherein position B1 is GIy. In another embodiment the acid stabilized insulin is an analogue of human insulin wherein position B3 is Lys, Thr, Ser, Ala or GIn.
  • the acid stabilized insulin is an analogue of human insulin wherein position B3 is Lys, Thr, Ser or Ala.
  • the acid stabilized insulin is an analogue of human insulin wherein position B3 is Lys or Ala.
  • the acid stabilized insulin is an analogue of human insulin wherein position B3 is Lys.
  • the acid stabilized insulin is an analogue of human insulin wherein position B3 is Lys and position B29 is GIu. In another embodiment the acid stabilized insulin is an analogue of human insulin wherein position B25 is deleted. In another embodiment the acid stabilized insulin is an analogue of human insulin wherein position B27 is deleted.
  • the acid stabilized insulin is an analogue of human insulin wherein position B30 is deleted. In another embodiment the acid stabilized insulin is an analogue of human insulin wherein position A18 is GIn.
  • the acid stabilized insulin is an analogue of human insulin wherein position A21 is Ala, Arg, GIn, GIu, GIy, His, lie, Leu, Met, Phe, Ser, Thr, Trp, Tyr, VaI or hSer. In another embodiment the acid stabilized insulin is an analogue of human insulin wherein position A21 is Ala, Arg, GIn, GIy, lie, Leu, Phe, Ser, Thr, VaI or hSer.
  • the acid stabilized insulin is an analogue of human insulin wherein position A21 is Ala or GIy.
  • the acid stabilized insulin is an analogue of human insulin wherein position A21 is GIy.
  • the acid stabilized insulin is a derivative of human insulin or an analogue thereof having one or more lipophilic substituents.
  • the acid stabilized insulin is a derivative of human insulin or an analogue thereof wherein the N ⁇ -amino group in position B29Lys is modified by covalent acylation with a hydrophobic moiety such as a fatty acid derivative or an litocholic acid derivative.
  • the acid stabilized insulin derivative is selected from the group consisting of B29N ⁇ -hexadecandioyl- ⁇ -Glu desB30 insulin, B29-N ⁇ -myristoyl-des(B30) human insulin, B29-N ⁇ -palmitoyl-des(B30) human insulin, B29-N ⁇ -myristoyl human insulin, B29-N ⁇ -palmitoyl human insulin, B28-N ⁇ -myristoyl Lys B28 Pro 829 human insulin, B28-N ⁇ - palmitoyl Lys B28 Pro B29 human insulin, B30-N ⁇ -myristoyl-Thr B29 Lys B30 human insulin, B30-N ⁇ - palmitoyl-Thr B29 Lys B30 human insulin, B29-N ⁇ -(N-palmitoyl- ⁇ -glutamyl)-des(B30) human insulin, B29-N ⁇ -(N-litho
  • the acid stabilized analogs of human insulin contain any combination of additional stabilizing substitutions.
  • the acid stabilized analogs of human insulin contain any combination of the additional stabilizing substitutions in positions B1 , B3, A18.
  • the acid stabilized insulin is an analogue of human insulin selected from the group consisting of:
  • the insulin is an analogue of human insulin selected from the group consisting of:
  • A21G, B9E, desB30 A21G, B9D, desB30
  • the insulin is an analogue of human insulin selected from the group consisting of: B1 G, A21G
  • the acid stabilized insulin is an analogue of human insulin from above three lists further modified in positions B3 and A18, eg B3T, B3S, B3Q and
  • the acid stabilized insulin is an analogue of human insulin from the above three lists further modified as follows: B3T, B28D
  • the acid stabilized insulin is an analogue of human insulin from the above three lists further modified by deletion of B30.
  • the insulin analogs and derivatives are selected from among those disclosed in EP 0 792 290 (Novo Nordisk MS), EP 0 214 826 and EP 0 705 275 (Novo Nordisk MS), US 5,504,188 (EIi Lilly), EP 0 368 187 (Aventis), US patents
  • insulins may include, but are not limited to, Lys B29 (N ⁇ -tetradecanoyl) des(B30) human insulin, Lys B29 -(N ⁇ -( ⁇ - glutamyl-N ⁇ -lithocholyl) des(B30) human insulin, N ⁇ B29 -octanoyl insulin, insulin glargine (insulin glargine, also known as Lantus®, differs from human insulin in that the amino acid aspar- agine at position A21 is replaced by glycine and two arginines are added to the C-terminus of the B-chain), insulin glulisine ( insulin glulisine, also known as Apidra®, differs from human insulin in that the amino acid asparagine at position B3 is replaced by lysine and the lysine in position B29 is replaced by glutamic acid) Lys B29 (N ⁇ -tetradecanoyl) des(B30) human insulin,
  • the acid stabilized insulin is a derivative of human insulin or a human insulin analogue where the derivative contains at least one lysine residue and a lipophilic substituent is attached to the epsilon amino group of the lysine residue.
  • the lysine residue to which the lipophilic substituent is attached is present at position B28 of the insulin peptide.
  • the lysine residue to which the lipophilic substituent is attached is present at position B29 of the insulin peptide.
  • lipophilic substituent is an acyl group corresponding to a carboxylic acid having at least 6 carbon atoms.
  • the lipophilic substituent is an acyl group, branched or unbranched, which corresponds to a carboxylic acid having a chain of carbon atoms 8 to 24 atoms long.
  • the lipophilic substituent is an acyl group corresponding to a fatty acid having at least 6 carbon atoms. In another embodiment, the lipophilic substituent is an acyl group corresponding to a linear, saturated carboxylic acid having from 6 to 24 carbon atoms.
  • the lipophilic substituent is an acyl group corresponding to a linear, saturated carboxylic acid having from 8 to 12 carbon atoms.
  • the lipophilic substituent is an acyl group corresponding to a linear, saturated carboxylic acid having from 10 to 16 carbon atoms.
  • the lipophilic substituent is an oligo oxyethylene group comprising up to 10, preferably up to 5, oxyethylene units.
  • the lipophilic substituent is an oligo oxypropylene group comprising up to 10, preferably up to 5, oxypropylene units.
  • the invention relates to an acid stabilized human insulin derivative in which the B30 amino acid residue is deleted or is any amino acid residue which can be coded for by the genetic code except Lys, Arg and Cys; the A21 and the B3 amino acid residues are, independently, any amino acid residues which can be coded for by the genetic code except Lys, Arg and Cys; Phe B1 may be deleted; the epsilon-amino group of Lys B29 has a lipophilic substituent which comprises at least 6 carbon atoms; and 2-A Zn 2+ ions may be bound to each insulin hexamer with the proviso that when B30 is Thr or Ala and A21 and B3 are both Asn, and Phe B1 is not deleted, then 2-A Zn 2+ ions are bound to each hexamer of the insulin derivative.
  • the invention relates to an acid stabilized human insulin derivative in which the B30 amino acid residue is deleted or is any amino acid residue which can be coded for by the genetic code except Lys, Arg and Cys; the A21 and the B3 amino acid residues are, independently, any amino acid residues which can be coded for by the genetic code except Lys, Arg and Cys, with the proviso that if the B30 amino acid residue is Ala or Thr, then at least one of the residues A21 and B3 is different from Asn; Phe B1 may be deleted; and the epsilon-amino group of Lys B29 has a lipophilic substituent which comprises at least 6 carbon atoms.
  • the invention relates to an acid stabilized human insulin derivative in which the B30 amino acid residue is deleted or is any amino acid residue which can be coded for by the genetic code except Lys, Arg and Cys; the A21 and the B3 amino acid residues are, independently, any amino acid residues which can be coded for by the genetic code except Lys, Arg and Cys; Phe B1 may be deleted; the epsilon-amino group of Lys B29 has a lipophilic substituent which comprises at least 6 carbon atoms; and 2-4 Zn 2+ ions are bound to each insulin hexamer.
  • the formulations of the invention contain acid stabilized insulin in a concentration from about 0.01 mM to about 2.OmM.
  • the formulations of the invention contain acid stabilized insulin in a concentration from about 0.01 mM to about 1.OmM.
  • the formulations of the invention contain acid stabilized insulin in a concentration from about 0.01 mM to about 0.5mM. In yet another embodiment, the formulations of the invention contain acid stabilized insulin in a concentration from about 0.01 mM to about 0.3mM.
  • the salt of protamine or other positively charged peptides to be included is to be a protamine salt other than protamine sulphate or a salt of other positively charged peptides where such salts include, but are not limited to, acetate, bromide , chloride, caproate, trifluoroacetate, HCO 3 , propionate, lactate, formiate, nitrate, citrate, monohydrogenphosphate, dihydrogenphosphate, tartrate, or perchlorate salts or mixtures of any two salts.
  • the salt of protamine or other positively charged peptides is selected from the group consisting of propionate, lactate, formiate, nitrate, acetate, citrate, caproate, monohydrogenphosphate, dihydrogenphosphate salts.
  • the salt of protamine or other positively charged peptides is selected from the group consisting of propionate, lactate, formiate, nitrate and acetate salts.
  • the salt of protamine or other positively charged peptides is selected from acetate salts.
  • the salt of protamine or other positively charged pep- tides to be included in the formulation of the invention is to be a mixture of two different salts
  • one salt will be acetate and the other salt is selected from the group consisting of propionate, lactate, formiate, and nitrate salts.
  • the molar ratio between the two different salts may be from 0.1 :1 to 1 :1.
  • Protamine refers to the generic name of a group of strongly basic proteins present in sperm cells in salt-like combination with nucleic acids.
  • protamines to be used together with insulin are obtained from e.g. salmon (salmine), rainbow trout (iridine), herring (clupeine), sturgeon (sturine), orspanish mackerel or tuna (thynnine) and a wide variety of salts of protamines are commercially available.
  • the peptide composition of a specific protamine may vary depending of which family, genera or species of fish it is obtained from.
  • Protamine usually contains four major components, i.e. single-chain peptides containing about 30-32 residues of which about 21-22 are arginines. The N-terminal is proline for each of the four main components, and since no other amino groups are present in the sequence, chemical modification of protamine by a particu- lar salt is expected to be homogenous in this context.
  • the protamine salts used in the present invention are from salmon.
  • the protamine salts used in the present invention are from herring. In another embodiment, the protamine salts used in the present invention are from rainbow trout. In another embodiment, the protamine salts used in the present invention are from tuna.
  • Positive charged peptides refers to peptides of which the net charge at near neutral pH and below that is positive.
  • positively charges peptides used in the present invention are peptides with at net charge at near neutral pH and below that is greater than or equal to +2 and a percentage of positively charged amino acids that is greater than or equal to 40%.
  • positively charges peptides used in the present invention are peptides with at net charge at near neutral pH and below that is greater than or equal to +4 and a percentage of positively charged amino acids that is greater than or equal to 40%.
  • positively charges peptides used in the present invention are peptides with at net charge at near neutral pH and below that is greater than or equal to +6 and a percentage of positively charged amino acids that is greater than or equal to 40%.
  • positively charged peptides used in the present invention are peptides comprising Arg(R) and/or Lys(K) residues.
  • positively charged peptides used in the present invention consist of Arginine(R) residues.
  • positively charged peptides used in the present invention consist of Lysine(K) residues. In another embodiment, positively charged peptides used in the present invention consist of Lysine(K) and Arginine(R) residues.
  • positively charged peptides used in the present invention equals parts of protamine sequences.
  • Arg X where X is from the following list (2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16) Lys x, where X is from the following list (2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16), and combinations thereof; and peptides that equals parts of protamine sequences exemplified by VSR 6 G 2 R 4 .
  • Examples of specific positively charged peptides are: R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , Rs, Rg, R 1 0, R 11 , Ri 2 , R 13 , Ri 4 , Ri5, R 1 6, K 1 , K 2 , K 3 , K 4 , K 5 , K 6 , K 7 , K 8 , K 9 , K 10 , K 11 , K 12 , K 13 , K 14 , K 15 , K 16
  • the molar ratio of salt of protamine or other positively charged peptides to acid stabilized insulin in the formulations of the invention is from about 0.01 to about 2.
  • the molar ratio of salt of protamine or other positively charged peptides to acid stabilized insulin in the formulations of the invention is from about 0.01 to about 1.
  • the formulation has a pH less than about 5.0 where the term "about” as used in connection with pH means + or - 0.1 pH units from the stated number.
  • the formulation has a pH less than about 4.5 .
  • the formulation has a pH less than about 4.2 .
  • pH of the formulations of the invention is quite stable in that only very minor pH-migrations in the formulations of the invention have been observed to occur over time (data not shown) and that these variations are typically the pH-meter to pH-meter variations that are normally observed in measuring the pH of formulations.
  • the formulations contain, in addition to an acid stabilized insulin and a salt of protamine or other positively charged peptides, at least one of the following components: a preservative, a divalent metal ion such as zinc, and an isotonicity agent.
  • the formulations contain, in addition to an acid stabilized insulin and a salt of protamine or other positively charged peptides, at least two of the following components: a preservative, a divalent metal ion such as zinc, and an isotonicity agent.
  • the formulations contain, in addition to an acid stabilized insulin and a salt of protamine or other positively charged peptides, all three of the following components: a preservative, a divalent metal ion such as zinc, and an isotonicity agent.
  • the formulation contains no divalent metal ion.
  • the preservative is selected from the group consisting of phenol, tricresol, methyl p-hydroxybenzoate, propyl p-hydroxybenzoate, 2-phenoxyethanol, butyl p- hydroxybenzoate, 2-phenylethanol, benzyl alcohol, chlorobutanol, and thiomerosal, or mixtures thereof.
  • the preservative is phenol or m-cresol.
  • the preservative is phenol.
  • the preservative is m-cresol.
  • the preservative is present in a concentra- tion from about 0.1 mg/ml to about 50 mg/ml, more preferably in a concentration from about 0.1 mg/ml to about 25 mg/ml, and most preferably in a concentration from about 0.1 mg/ml to about 10 mg/ml.
  • the divalent metal ion may be calcium, magnesium or zinc or a combination thereof.
  • the divalent metal ion is zinc.
  • the concentration of zinc in the formulations of the invention is less than a molar ratio of 3 Zn 2+ per insulin.
  • the concentration of zinc in the formulations of the invention is less than a molar ratio of 2 Zn 2+ per insulin.
  • the concentratjon of zinc in the formulations of the invention is less than a molar ratio of 1 Zn 2+ per insulin.
  • the isotonicity agent may be selected from the group consisting of glycerol, mannitol, propylene glycol, dimethyl sulfone, methyl sulfonyl methane, trehalose, sucrose, sorbitol, saccarose and/or lactose or mixtures thereof.
  • the isotonicity agent is glycerol.
  • the isotonicity agent is present in a concentration from about 0.5% to about 3%, more preferably in a concentration from about 1 % to about 2%, and most preferably in a concentration from about 1.6%.
  • a buffer may be included in the formulations of the invention.
  • the buffer is selected from the group consisting of sodium acetate, sodium carbonate, citrate, glycylgly- cine, histidine, glycine, lysine, arginin, sodium dihydrogen phosphate, disodium hydrogen phosphate, sodium phosphate, and tris(hydroxymethyl)-aminomethan, or mixtures thereof.
  • the buffer is glycylglycine, sodium dihydrogen phosphate, disodium hydrogen phosphate, sodium phosphate or mixtures thereof.
  • the formulation may further comprise a stabiliser selected from the group of high molecular weight polymers or low molecular compounds where such stabilizers include, but are not limited to, polyethylene glycol (e.g. PEG 3350), polyvinylalcohol (PVA), polyvinylpyrrolidone, carboxymethylcellulose, different salts (e.g. sodium chloride), L-glycine, L-histidine, imidazole, arginine, lysine, isoleucine, aspartic acid, tryptophan, threonine and mixtures thereof.
  • a stabiliser is selected from the group consisting of L-histidine, imidazole and arginine.
  • the high molecular weight polymer is present in a concentration from 0.1 mg/ml to 50mg/ml. In a further embodiment of the invention the high molecular weight polymer is present in a concentration from 0.1 mg/ml to 5mg/ml. In a further embodiment of the invention the high molecular weight polymer is present in a concentration from 5mg/ml to 10mg/ml. In a further embodiment of the invention the high molecular weight polymer is present in a concentration from 0mg/ml to 20mg/ml. In a further embodiment of the invention the high molecular weight polymer is present in a concentration from 20mg/ml to 30mg/ml. In a further embodiment of the invention the high molecular weight polymer is present in a concentration from 30mg/ml to 50mg/ml.
  • the low molecular weight compound is present in a concentration from 0.1 mg/ml to 50mg/ml. In a further embodiment of the invention the low molecular weight compound is present in a concentration from 0.1 mg/ml to 5mg/ml. In a further embodiment of the invention the low molecular weight compound is present in a concentration from 5mg/ml to 10mg/ml. In a further embodiment of the invention the low molecular weight compound is present in a concentration from 10mg/ml to 20mg/ml. In a further embodiment of the invention the low molecular weight compound is present in a concentration from 20mg/ml to 30mg/ml. In a further embodiment of the invention the low mo- lecular weight compound is present in a concentration from 30mg/ml to 50mg/ml.
  • the formulation of the invention may further comprise a surfactant where a surfactant may be selected from a detergent, ethoxylated castor oil, polyglycolyzed glycerides, acetylated monoglycerides, sorbitan fatty acid esters, polysorbate, such as polysorbate-20, block copolymers as polyethyleneoxide/polypropylene- oxide block copolymers such as poloxamers, poloxamer 188 and poloxamer 407, Brij ® 35, Brij ® 56, Brij ® 72, Brij ® 76, Brij ® 92V, Brij ® 97, Brij ® 58P, Cremophor ® EL, Decaethylene glycol monododecyl ether, N-Decanoyl-N-methylglucamine, n-Dodecanoyl-N-methylglucamide, alkyl-polyglucosides, ethoxyl
  • a surfactant
  • N-alkyl-N,N-dimethyl- ammonio-1 -propanesulfonates 3-cholamido-1 -propyldimethylammonio-1 -propanesulfonate, dodecylphosphocholine, myristoyl lysophosphatidylcholine, hen egg lysolecithin), cationic surfactants (quarternary ammonium bases) (e.g.
  • acylcarnitines and derivatives N ⁇ -acylated derivatives of lysine, arginine or histidine, or side-chain acylated derivatives of lysine or arginine, N ⁇ -acylated derivatives of dipeptides comprising any combination of lysine, arginine or histidine and a neutral or acidic amino acid, N ⁇ -acylated derivative of a tripeptide comprising any combination of a neutral amino acid and two charged amino acids, or the surfactant may be selected from the group of imidazoline derivatives, or mixtures thereof. Each one of these specific surfactants constitutes an alternative embodiment of the invention.
  • the surfactant is poloxamer 188 or TWEEN ® 20. In another preferred embodiment of the invention the surfactant is poloxamer 188. In another preferred embodiment of the invention the surfactant is TWEEN ® 20.
  • the surfactant is present in an amount less that 200ppm, more preferably in an amount less that 100ppm, and most preferably in an amount less that 50ppm.
  • compositions of the invention may be prepared by conventional techniques, e.g. as described in Remington's Pharmaceutical Sciences, 1985 or in Remington: The Science and Practice of Pharmacy, 19 th edition, 1995, where such conventional techniques of the pharmaceutical industry involve dissolving and mixing the ingredients as appropriate to give the desired end product.
  • the present invention also relates to methods of making the formulations of the invention.
  • the method for preparing formulations of the invention comprises: a) preparing a solution by dissolving a divalent metal ion in water or buffer; b) preparing a solution by dissolving the preservative in water or buffer; c) preparing a solution by dissolving the isotonicity agent in water and buffer d) preparing a solution by dissolving the surfactant in water or buffer; e) preparing a solution by dissolving the acid stabilized insulin in water or buffer; f) preparing a solution by dissolving a salt of protamine or other positively charged peptides in buffer or water; g) mixing solution e) and one or more of solutions a), b), c), and d); h) mixing solution g) with solution f); and i) adjusting the pH of the mixture in h)l to the desired pH of less than 5.0.
  • a solution containing acid stabilized insulin and optionally a preservative, an isotonicity agent and/or a divalent metal ion in water or a buffer at a pH of about 6.5 to about 7.5, preferably at about neutral pH can be mixed with a solution of a salt of protamine or other positively charged peptides, and then the pH of the mixed solution can be adjusted to the desired final pH of less than 5.0.
  • the solution of the salt to be used in the above mixtures can be prepared by dissolving each salt separately and then mixing the solutions together or by dissolving the salts together in one volume of water or buffer.
  • the present invention further relates to methods of treatment using the pharmaceutical formulations of the invention where the compositions are administered in an amount effective to combat the disease, condition, or disorder for which administration of the insulin peptide contained in the formulation is indicated.
  • the formulations of the invention may be used in the treatment of type 1 and type 2 diabetes.
  • the dose, route of administration, and number of administrations per day of a formulation of the invention will be determined by a physician taking into account such factors as the therapeutic objectives, the nature and cause of the patient's disease, other drugs or medications the patient might be taking, the patient's gender and weight, level of exercise and eating habits as well as other factors that might be known to the physician.
  • the daily dose of insulin to be administered to a patient in the formulations of the invention is from about 0.1 units of insulin/kg of body weight to about 1 unit of insulin/kg of body weight.
  • the daily dose of insulin to be administered to a patient in the formulations of the invention is from about 0.2 units of insulin/kg of body weight to about 0.6 units of insulin/kg of body weight.
  • concentration ranges of insulin used to treat a diabetic patient may vary depending on whether, for example, the patient to be treated is a child with type 1 diabetes or an adult with strongly insulin resistant type 2 diabetes.
  • the physician of ordinary skill in treating diabetes will also be able to select the therapeutically most advantageous method for administering the formulations of the invention.
  • the formulations may be administered parenterally where typical routes of parenteral administration are subcutaneous and intramuscular. In another embodiment, the formulations may be administered parenterally where the route is subcutane- ous.
  • the formulations may be administered by nasal, buccal, pulmonary or ocular routes. In another embodiment, the formulations may be administered by nasal route. In another embodiment, the formulations may be administered by pulmonary route. In one embodiment the formulations of the invention are used in connection with insulin pumps.
  • the insulin pumps may be prefilled and disposable, or the insulin formulations may be supplied from a reservoir which is removable. Insulin pumps may be skin-mounted or carried, and the path of the insulin preparation from the storage compartment of the pump to the patient may be more or less tortuous.
  • Non-limiting examples of insulin pumps are dis- closed in US 5,957,895, US 5,858,001 , US 4,468,221 , US 4,468,221 , US 5,957,895, US 5,858,001 , US 6,074,369, US 5,858,001 , US 5,527,288, and US 6,074,369.
  • the formulations of the invention are used in connection with pen-like injection devices, which may be prefilled and disposable, or the insulin formulations may be supplied from a reservoir which is removable.
  • pen-like in- jection devices are FlexPen ® , InnoLet ® , InDuoTM, Innovo ® .
  • formulations of the invention are used in connection with devices for pulmonary administration of aqueous insulin formulations, a non-limiting example of which is the AerX ® device.
  • the invention furthermore relates to treatment of a patient in which the pharmaceu- tical formulations of the invention are combined with another form of treatment.
  • treatment of a patient with the pharmaceutical formulations of the invention is combined with diet and/or exercise.
  • the pharmaceutical formulations of the invention are administered in combination with one or more further active substances in any suitable ratios where "in combination with” as used in connection with the pharmaceutical formulations of the invention and one or more further active substances means that the one or more further active substances may be included within the formulation of the invention or they may be contained in separate formulation(s) from the formulation of the invention.
  • Such further active substances may e.g. be selected from antiobesity agents, antidiabetics, antihypertensive agents, agents for the treatment of complications resulting from or associated with diabetes and agents for the treatment of complications and disorders resulting from or associated with obesity.
  • the pharmaceutical formulations of the invention may be administered in combination with one or more antiobesity agents or appetite regulating agents.
  • agents may be selected from the group consisting of CART (cocaine amphetamine regulated transcript) agonists, NPY (neuropeptide Y) antagonists, MC4 (melanocortin 4) agonists, MC3 (melanocortin 3) agonists, orexin antagonists, TNF (tumor necrosis factor) agonists, CRF (corticotropin releasing factor) agonists, CRF BP (corticotropin releasing factor binding protein) antagonists, urocortin agonists, ⁇ 3 adrenergic agonists such as CL-316243, AJ- 9677, GW-0604, LY362884, LY377267 or AZ ⁇ 0140, MSH (melanocyte-stimulating hormone) agonists, MCH (melanocyte-concentrating hormone) antagonist
  • the antiobesity agent is leptin.
  • the antiobesity agent is dexamphetamine or amphetamine.
  • the antiobesity agent is fenfluramine or dexfenfluramine. In still another embodiment the antiobesity agent is sibutramine.
  • the antiobesity agent is orlistat. In another embodiment the antiobesity agent is mazindol or phentermine. In still another embodiment the antiobesity agent is phendimetrazine, diethylpropion, fluoxetine, bupropion, topiramate or ecopipam.
  • the orally active hypoglycemic agents comprise imidazolines, sulphonylureas, biguanides, meglitinides, oxadiazolidinediones, thiazolidinediones, insulin sensitizers, insulin secretagogues such as glimepride, ⁇ -glucosidase inhibitors, agents acting on the ATP- dependent potassium channel of the ⁇ -cells eg potassium channel openers such as those disclosed in WO 97/26265, WO 99/03861 and WO 00/37474 (Novo Nordisk A/S) which are incorporated herein by reference, or mitiglinide, or a potassium channel blocker, such as BTS-67582, nateglinide, glucagon antagonists such as those disclosed in WO 99/01423 and WO 00/39088 (Novo Nordisk A/S and Agouron Pharmaceuticals, Inc.), which are incorporated herein by reference, GLP-1 agonists such as those disclosed in WO
  • the pharmaceutical formulations of the invention are administered in combination with a sulphonylurea e.g. tolbutamide, chlorpropamide, tolazamide, glibenclamide, glipizide, glimepiride, glicazide or glyburide.
  • a sulphonylurea e.g. tolbutamide, chlorpropamide, tolazamide, glibenclamide, glipizide, glimepiride, glicazide or glyburide.
  • the pharmaceutical formulations of the invention are administered in combination with a biguanide, e.g. metformin.
  • the pharmaceutical formulations of the invention are administered in combination with a meglitinide eg repaglinide or nateglinide.
  • the pharmaceutical formulations of the invention are administered in combination with a thiazolidinedione insulin sensitizer, e.g. tro- glitazone, ciglitazone, pioglitazone, rosiglitazone, isaglitazone, darglitazone, englitazone, CS- 01 1/CI-1037 or T 174 or the compounds disclosed in WO 97/41097, WO 97/41 119, WO 97/41 120, WO 00/41 121 and WO 98/45292 (Dr. Reddy's Research Foundation), which are incorporated herein by reference.
  • a thiazolidinedione insulin sensitizer e.g. tro- glitazone, ciglitazone, pioglitazone, rosiglitazone, isaglitazone, darglitazone, englitazone, CS- 01 1/CI-1037 or T 174 or the compounds disclosed in WO 97/
  • the pharmaceutical formulations of the invention may be administered in combination with an insulin sensitizer, e.g. such as Gl 262570, YM-440, MCC-555, JTT-501 , AR-H039242, KRP-297, GW-409544, CRE-16336, AR-H049020, LY510929, MBX-102, CLX-0940, GW-501516 or the compounds disclosed in WO 99/19313, WO 00/50414, WO 00/63191 , WO 00/63192, WO 00/63193 (Dr.
  • an insulin sensitizer e.g. such as Gl 262570, YM-440, MCC-555, JTT-501 , AR-H039242, KRP-297, GW-409544, CRE-16336, AR-H049020, LY510929, MBX-102, CLX-0940, GW-501516 or the compounds disclosed in WO 99/19313, WO 00/5
  • the pharmaceutical formulations of the invention are administered in combination with an ⁇ -glucosidase inhibitor, e.g. voglibose, emiglitate, miglitol or acarbose.
  • an ⁇ -glucosidase inhibitor e.g. voglibose, emiglitate, miglitol or acarbose.
  • the pharmaceutical formulations of the invention are administered in combination with an agent acting on the ATP-dependent potas- sium channel of the ⁇ -cells, e.g. tolbutamide, glibenclamide, glipizide, glicazide, BTS-67582 or repaglinide.
  • an agent acting on the ATP-dependent potas- sium channel of the ⁇ -cells e.g. tolbutamide, glibenclamide, glipizide, glicazide, BTS-67582 or repaglinide.
  • the pharmaceutical formulations of the invention may be administered in combination with nateglinide.
  • the pharmaceutical formulations of the invention are administered in combination with an antilipidemic agent, e.g. cholestyramine, colestipol, clofibrate, gemfibrozil, lovastatin, pravastatin, simvastatin, probucol or dextrothyro- xine.
  • an antilipidemic agent e.g. cholestyramine, colestipol, clofibrate, gemfibrozil, lovastatin, pravastatin, simvastatin, probucol or dextrothyro- xine.
  • the pharmaceutical formulations of the invention are administered in combination with more than one of the above-mentioned compounds, e.g. in combination with metformin and a sulphonylurea such as glyburide; a sulphonylurea and acarbose; nateglinide and metformin; acarbose and metformin; a sulphonylurea, metformin and troglitazone; metformin and a sulphonylurea; etc.
  • metformin and a sulphonylurea such as glyburide
  • a sulphonylurea and acarbose such as glyburide
  • a sulphonylurea and acarbose such as glyburide
  • a sulphonylurea and acarbose such as glyburide
  • the pharmaceutical formulations of the invention may be administered in combination with one or more antihypertensive agents.
  • antihypertensive agents are ⁇ -blockers such as alprenolol, atenolol, timolol, pindolol, propranolol and metoprolol, ACE (angiotensin converting enzyme) inhibitors such as benazepril, captopril, enalapril, fosinopril, lisinopril, quinapril and ramipril, calcium channel blockers such as nifedipine, felodipine, nicer- dipine, isradipine, nimodipine, diltiazem and verapamil, and ⁇ -blockers such as doxazosin, urapidil, prazosin and terazosin.
  • the pharmaceutical preparation of the invention may also be combined with NEP inhibitors such as candoxatril.
  • the monomeric insulin compounds are eluted isocratically/gradiently with a phosphate buffer, pH 7,2 contain- ing sodium sulphate and approximately 7,7% (W/W) acetonitrile. - 2 minutes isocratically 20% buffer B (65,5% acetonitrile) followed by 1 min gradient step with increased acetonitrile concentration, 20 to 50% buffer B, for elution of the more hydrophobic compounds.
  • Figure 1 shows the solubility of human insulin, B28D insulin and A21G, B28D, desB30 insulin in standard formulation as described with different concentrations of pro- tamine acetate.
  • this standard formulation of 0.6mM insulin the solubility of insulin at neutral pH is gradually reduced upon addition of protamine acetate leading to a complete precipitation of insulin at a protamine acetate concentration of 0.3mM.
  • n 1-20.
  • Fmoc-removal The resin was treated with piperidine/NMP/DBU 20/80/2 for a period of 10 min, drained and again retreated as above for 2h.
  • Fmoc-protected Rink amide AM resin (NovaBiochem, 0.68 mmol/g, 14.7 g, 10 mmol) was used to prepare resin bound Fmoc-(Arg(Pbf)) 6 by the solid phase peptide synthesis protocol (I). The following amounts were used for each coupling: Fmoc-Arg(Pbf)-OH 19,44 g (30 mmol), HOAt 4.04 g (30 mmol) and DIC 4,67 ml. (30 mmol) in NMP (50 ml_). Capping: AcOH 3.36 ml_, HOBt 7.93 g and DIC12.0 ml. in NMP (25 ml_). De-Fmoc conditions: As in protocol (I).
  • This compound was prepared from the Fmoc-(Arg(Pbf)) 6 derivative above, adding two more double couplings. Cleavage and purification as above.
  • Praep Gilson HPLC; Column: Jones, Kromasil RP18 5 ⁇ m 15x225 mm: Rt 7.5 min, Flow:10 ml/ min, Eluent:: water/ acetonitril/0,1% TFA. Gradient: 0 -1 min: 10 % CH3CN, 1-20 min:10 % CH3CN to 50 % CH3CN, 20-25 min 50 % CH3CN.
  • MALDI (matrix CHCA); m/z:1267.
  • This compound was prepared from the Fmoc-(Arg(Pbf)) 6 derivative above adding 6 more double couplings. Cleavage and purification as above.
  • Praep Gilson HPLC Column: Jones, Kromasil RP18 5 ⁇ m 15x225 mm: Rt. 7-8 min,
  • MALDI- MS m/z 1887.6 (Matrix: Sinnapinic acid).
  • a pharmaceutical formulation which is a solution comprising an acid stabilized insulin, and a salt of protamine or other positively charged peptides, wherein said salt is present in said formulation in a concentration of greater than 0.01 mM and wherein said formulation has a pH of less than about 5.0.
  • a method of treating type 1 or type 2 diabetes comprising administering to a patient in need of such treatment an effective amount of a formulation according to any of the clauses 1-18.
  • a formulation according to any of the clauses 1-18 wherein the salt of protamine or other positively charged peptides is selected from the group consisting of propionate, lactate, formiate, nitrate and acetate salts.
  • a method of treating type 1 or type 2 diabetes comprising administering to a patient in need of such treatment an effective amount of a formulation according to any of the clausems 20-26.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des formules pharmaceutiques comprenant de l'insuline stabilisée vis-à-vis des acides, ainsi qu'un sel de protamine ou d'un autre peptide positivement chargé, des méthodes d'élaboration de telles formules, et les applications de telles formules dans le traitement de maladies et d'états pathologiques dans lesquels l'utilisation du ou des peptides d'insuline contenus dans de telles formules est indiquée.
PCT/EP2007/054863 2006-05-24 2007-05-21 Formules solubles stables contenant de l'insuline WO2007135118A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06114528 2006-05-24
EP06114528.0 2006-05-24

Publications (1)

Publication Number Publication Date
WO2007135118A1 true WO2007135118A1 (fr) 2007-11-29

Family

ID=37433978

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/054863 WO2007135118A1 (fr) 2006-05-24 2007-05-21 Formules solubles stables contenant de l'insuline

Country Status (1)

Country Link
WO (1) WO2007135118A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3069437A1 (fr) * 2017-07-28 2019-02-01 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant au moins de l'insuline humaine a21g et un suppresseur de glucagon a action prandiale
FR3069436A1 (fr) * 2017-07-27 2019-02-01 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant au moins de l'insuline humaine a21g et un suppresseur de glucagon a action prandiale
WO2019020820A3 (fr) * 2017-07-27 2019-03-28 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant au moins l'insuline humaine a21g et un suppresseur de glucagon a action prandiale
FR3082426A1 (fr) * 2018-06-14 2019-12-20 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant au moins de l'insuline humaine a21g et un suppresseur de glucagon a action prandiale
WO2020012040A1 (fr) * 2018-07-13 2020-01-16 Adocia Formulation thermostable d'insuline humaine a21g
CN111658604A (zh) * 2014-01-09 2020-09-15 赛诺菲 胰岛素类似物和/或胰岛素衍生物的稳定化不含甘油的药物制剂

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268335B1 (en) * 1997-10-24 2001-07-31 Eli Lilly And Company Insoluble insulin compositions
WO2004096266A1 (fr) * 2003-05-02 2004-11-11 Novo Nordisk A/S Stabilite physique amelioree de preparations d'insuline
WO2006005683A1 (fr) * 2004-07-09 2006-01-19 Novo Nordisk A/S Preparations pharmaceutiques contenant de l'insuline

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268335B1 (en) * 1997-10-24 2001-07-31 Eli Lilly And Company Insoluble insulin compositions
WO2004096266A1 (fr) * 2003-05-02 2004-11-11 Novo Nordisk A/S Stabilite physique amelioree de preparations d'insuline
WO2006005683A1 (fr) * 2004-07-09 2006-01-19 Novo Nordisk A/S Preparations pharmaceutiques contenant de l'insuline

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111658604A (zh) * 2014-01-09 2020-09-15 赛诺菲 胰岛素类似物和/或胰岛素衍生物的稳定化不含甘油的药物制剂
FR3069436A1 (fr) * 2017-07-27 2019-02-01 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant au moins de l'insuline humaine a21g et un suppresseur de glucagon a action prandiale
WO2019020820A3 (fr) * 2017-07-27 2019-03-28 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant au moins l'insuline humaine a21g et un suppresseur de glucagon a action prandiale
US10610572B2 (en) 2017-07-27 2020-04-07 Adocia Compositions in the form of an injectable aqueous solution including at least human insulin A21G and a glucagon suppressor with prandial action
US11065305B2 (en) 2017-07-27 2021-07-20 Adocia Compositions in the form of an injectable aqueous solution including at least human insulin A21G and a glucagon suppressor with prandial action
EP4019039A1 (fr) * 2017-07-27 2022-06-29 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant au moins une insuline humaine a21g et un suppresseur de glucagon a action prandiale
FR3069437A1 (fr) * 2017-07-28 2019-02-01 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant au moins de l'insuline humaine a21g et un suppresseur de glucagon a action prandiale
FR3082426A1 (fr) * 2018-06-14 2019-12-20 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant au moins de l'insuline humaine a21g et un suppresseur de glucagon a action prandiale
WO2020012040A1 (fr) * 2018-07-13 2020-01-16 Adocia Formulation thermostable d'insuline humaine a21g
FR3083700A1 (fr) * 2018-07-13 2020-01-17 Adocia Formulation thermostable d'insuline humaine a21g
US20210315977A1 (en) * 2018-07-13 2021-10-14 Adocia Thermostable formulation of a21g human insulin

Similar Documents

Publication Publication Date Title
US8263551B2 (en) Soluble, stable insulin-containing formulations with a protamine salt
WO2007135117A2 (fr) Formulations solubles stables contenant de l'insuline
US9034818B2 (en) Pharmaceutical formulations comprising an insulin derivative
JP5026567B2 (ja) インスリン組成物および組成物の製造方法
US20080280814A1 (en) Pharmaceutical Compositions Containing Insulin and Insulinotropic Peptide
US5866538A (en) Insulin preparations containing NaCl
EP0921812B1 (fr) Preparations d'insuline contenant du halogenide
EP1644411A2 (fr) Compositions d'insuline stabilisee
CA2545034A1 (fr) Formulations peptidiques a base de propylene glycol optimales pour la production et l'utilisation dans des dispositifs d'injection
US20220002373A1 (en) Single-chain insulin analogues with poly-alanine c-domain sub-segments
JP2002500196A (ja) 安定化させたインスリン組成物
KR20130092972A (ko) 인슐린-아연 복합체의 제조 방법
US20150299286A1 (en) Glutamic acid-stabilized insulin analogues
US20110245163A1 (en) Stabilised Insulin Compositions
WO2007135118A1 (fr) Formules solubles stables contenant de l'insuline
JP2019535733A (ja) 安定性が増強された速効性インスリン類似体
WO2004096266A1 (fr) Stabilite physique amelioree de preparations d'insuline

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07729307

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07729307

Country of ref document: EP

Kind code of ref document: A1